Shockwave Medical, Inc. (SWAV)
After hours:
| Previous close | 330.38 |
| Open | 330.70 |
| Bid | 304.06 x 200 |
| Ask | 357.19 x 200 |
| Day's range | 330.00 - 330.94 |
| 52-week range | 157.00 - 331.58 |
| Volume | |
| Avg. volume | 1,118,125 |
| Market cap | 12.389B |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | 85.49 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Shockwave Medical Reports First Quarter 2024 Financial Results
SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. “The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of ou
- GlobeNewswire
Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study
Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory AnginaSANTA CLARA, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced that investigators presented six-month data from the full population of the REDUCER-I study, alongside interim long-term follow-up results
- Business Wire
Johnson & Johnson to Acquire Shockwave Medical
NEW BRUNSWICK, N.J. & SANTA CLARA, Calif., April 05, 2024--Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) ("Shockwave") today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired. The transaction was approved by both companies’ boards of directors.
